Key TakeawaysJPMorgan initiated coverage on HIMS with a Neutral stance and $32 price objective, representing approximately 16% potential gain from present levelsAnalysts highlight concerns regarding the company’s strategic pivot from compounded GLP-1 medications to FDA-sanctioned branded alternatives such as WegovyThrough its collaboration with Novo Nordisk, the telehealth platform delivered more than 125,000 Wegovy orders within the initial six-week periodSecond-quarter revenue reached $753.21 million, reflecting a 38.2% year-over-year increase, though the firm significantly underperformed on profitability with a $0.37 per share loss against consensus expectations of a $0.05 lossAdditional challenges stem from an FTC regulatory complaint and ongoing securities litigationHIMS began Friday’s session at $27.52, substantially below its 52-week peak of $65.30. The $32 valuation from JPMorgan suggests measured optimism rather than strong bullishness. Shares declined roughly 1% during trading.Hims & Hers Health, Inc., HIMSInvestment analyst Bryan Smilek from JPMorgan launched coverage with a Neutral assessment, acknowledging the firm’s impressive expansion while highlighting meaningful implementation challenges connected to its GLP-1 product transformation.The telehealth provider announced in March its decision to cease marketing compounded GLP-1 treatments and transition completely to branded, FDA-sanctioned medications. This strategic shift introduces uncertainty. Compounded product sales are declining as branded prescription volumes continue building.Smilek forecasts 2026 GLP-1 revenue reaching $1.1 billion, representing 46% year-over-year growth, fueled by the Novo Nordisk collaboration. His analysis suggests the Wegovy arrangement should sufficiently offset losses from discontinued compounded sales.The Novo collaboration started strongly. The platform processed over 125,000 Wegovy orders during the initial six-week window.JPMorgan identifies substantial opportunity in the GLP-1 sector. The investment firm projects U.S. cash-paying GLP-1 consumers could expand from approximately 2.8 million currently to beyond 8 million by 2030.Management is pursuing 2030 revenue exceeding $6.5 billion with adjusted EBITDA surpassing $1.3 billion, powered by global expansion and additional product categories including peptide therapies.Financial PerformanceRecent quarterly results presented contrasting signals. Revenue of $753.21 million exceeded the $698.90 million consensus and increased 38.2% year over year.However, profitability proved disappointing. The firm recorded a loss of $0.37 per share, significantly worse than the anticipated loss of $0.05. This substantial shortfall concerned investors.Shares fell 7.7% after the earnings announcement, according to Zacks, demonstrating HIMS’s vulnerability to profitability concerns.Regulatory and Legal ChallengesBeyond disappointing earnings, HIMS confronts two regulatory issues. The FTC has filed a complaint alleging misleading and illegal privacy practices. Additionally, a securities class action encompasses shareholders who owned HIMS between August 2025 and July 2026, with a lead-plaintiff filing deadline of November 2, 2026.While neither matter has reached resolution, both create additional uncertainty.Wall Street consensus reflects a Hold recommendation. Among 16 analysts monitored by MarketBeat, 12 assign Hold ratings, three recommend Buy, and one suggests Sell. The consensus price objective stands at $32.43.JPMorgan’s Smilek indicates he needs evidence that the branded GLP-1 transition succeeds, emerging specialties demonstrate sustainable growth, and profit margins improve before adopting a more optimistic stance.Company insiders have reduced positions. During the past 90 days, insiders disposed of 190,227 shares valued at more than $6.1 million.The post JPMorgan Assigns Neutral Rating to Hims & Hers (HIMS) Stock Amid GLP-1 Strategy Transition appeared first on Blockonomi.